AUSTIN, Texas, Jan. 17, 2024 /PRNewswire/ — L7 Informatics, the industry leader providing scientific software solutions for research, development, manufacturing, and quality control operations, is excited to announce a strategic partnership with Cellipont Bioservices, a distinguished CDMO specializing in cell therapy manufacturing. This collaboration marks a pivotal moment as Cellipont embraces L7 Informatics’ L7|ESP™ unified

Houston, TX, October 11, 2023/ PRNewswire/— Cellipont Bioservices, a leading CDMO in cell therapy development and manufacturing and Evia Bio, a life sciences innovation company that develops non-DMSO cryopreservation solutions for the cell therapy industry, announced today a strategic partnership to launch a Cryopreservation Excellence Center (CryoX) at Cellipont Bioservices cGMP cell therapy manufacturing facilities

Cellipont Bioservices, a leading CDMO in cell therapy development and manufacturing and Diakonos Oncology, announced today that they have entered into an agreement for the Process Development & cGMP Manufacturing of DOC1021, an

Cellipont Bioservices announced today that Daniel Ramirez has joined the executive leadership team to oversee operations at the company’s new cell therapy manufacturing site in The Woodlands, Texas. The site is scheduled to come online in stages

Cellipont Bioservices announced today that Madhavi Anumula has joined the company as Vice President of Process Development. With more than 17 years of industry experience, Madhavi brings a wealth of expertise in cellular therapies to her

Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO) with locations in San Diego and Houston, announced two additions to its commercial leadership team. Brian Walsh joined the company as Senior Vice

Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), celebrated the start of construction for its new 76,000 sq. ft. commercial-ready, state-of-the-art manufacturing facility for cell therapies and gene-

Cellipont Bioservices, a contract development and manufacturing organization (CDMO) specializing in cell therapies and gene-modified cell therapies, today announced the addition of Stella Vnook as Chief Scientific Officer. Stella brings to Cellipont

Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), today announced plans for a 76,000 sq. ft. commercial-ready manufacturing facility for cell therapies and gene-modified cell therapies. Located in The

Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), today announced plans to expand its development and manufacturing facility at its Poway, California location. The expansion will enable Cellipont to